Atlanta 1/21/2013 11:25:58 PM
News / Financial Services

Lpath Inc (Stock Symbol: NASDAQ: LPTN) is now on

Lpath Inc has joined Now Stock Brokers, Brokerage Firms and Investors/Shareholders from around the world who follow Lpath Inc can link directly to Lpath Inc Link My Stock Hub. Brokers and Brokerage Firms that link to Lpath Inc typically are familiar with the company and can facilitate transactions in Lpath Inc security. Investors linking to Lpath Inc usually are either existing shareholders looking to stay informed when Lpath Inc posts new information or people that are simply interested in Lpath Inc that are not yet or may never become shareholders.

LinkMyStock is a premier financial networking platform designed specifically for public companies, brokerage firms, brokers and investors. provides a network that consists of brokers, brokerage firms and investors that can link directly to the companies that they follow. With brokers from around the world having the ability to select companies to link to that are members of Link My Stock this provides investors with the ability to locate brokers and contact them to find out more information about a company they are interested in learning more about.  provides every member with their own hub where they post content. Content sections include; press releases, blogs, pictures, videos, Right Now status updates, events, jobs and more in order to attract more visitors and increase the number of search results along with improving indexing.

To link to the Lpath Inc.'s Link My Stock Hub sign into your Link My Stock Hub or Join Link My Stock today.

About Lpath Inc

Lpath, Inc. is the category leader in the discovery and development of monoclonal antibodies that target (neutralize) bioactive lipids. The study of lipids (called lipidomics) is an emerging field of research that has already identified dozens of bioactive lipids that contribute to disease, with the promise of hundreds more as funding in the area continues to accelerate. Once a disease-causing lipid is identified, however, the challenge becomes one of generating a compound that neutralizes the relevant bioactive lipid. With its ImmuneY2™ platform technology and robust patent estate, Lpath is uniquely positioned to meet such challenges and exploit these opportunities.